Summit Partners sells Dreampath Diagnostics to Halma
The deal adds automated diagnostic testing platforms for immunochemistry and molecular testing to Halma's healthcare portfolio, serving hospitals and clinical laboratories.
Summit Partners has sold Dreampath Diagnostics, a manufacturer of automated diagnostic testing platforms, to UK-based health and safety technology group Halma.
Dreampath's systems, used for immunochemistry and molecular testing, serve hospital and clinical laboratory customers in the in-vitro diagnostics market.
Halma, a global group of life-saving technology companies, will integrate the business into its healthcare portfolio, broadening its capabilities in the diagnostics sector.
Summit Partners backed Dreampath in 2019, guiding the company's growth through this exit.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.